CAR-T therapy and historical trends in effectiveness and cost – effectiveness of oncology treatments

Written by RegMedNet

In this review, published in the Journal of Comparative Effectiveness Research, learn how CAR-T effectiveness and cost compares with traditional anticancer treatments.

CAR-T therapy has demonstrated enormous promise in recent years but despite numerous technical advances remains very expensive per dose. In this research article, published in the Journal of Comparative Effectiveness Research, Baumgardner et al used the Cost–Effectiveness Analysis Registry of the Tufts Medical Center (MA, USA) to assess effectiveness and cost-effectiveness compared with other recent anticancer treatments.

In the study, the team from Precision Health Economics (LA, USA) and Novartis Pharmaceuticals Corporation (NJ, USA) used registry data, the Institute for Clinical and Economic Review’s analysis of CAR-T therapies and information from the FDA to conduct graphical and multivariable analyses.

Find out the results>>


Click here to read your free article>>


Return to the spotlight homepage.